{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:58:41Z","timestamp":1794607121760,"version":"4.9.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamaneurol.2020.2703","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T14:56:53Z","timestamp":1597071413000},"page":"1536","source":"Crossref","is-referenced-by-count":132,"title":["Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.1001","volume":"77","author":[{"given":"Daniel B.","family":"Rubin","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al Jarrah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"LaRose","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Monk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Basil","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Spendley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikas","family":"Vaitkevicius","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"noi200056r1","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management.","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"26","key":"noi200056r2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell lymphomas.","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"noi200056r3","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen Receptor-modified T cells after failure of ibrutinib.","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"noi200056r4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"noi200056r5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"noi200056r6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy.","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"9","key":"noi200056r7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/CCM.0000000000003258","article-title":"Management of the critically ill adult chimeric antigen receptor-t cell therapy patient: a critical care perspective.","volume":"46","author":"Gutierrez","year":"2018","journal-title":"Crit Care Med"},{"issue":"8","key":"noi200056r8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia.","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"20","key":"noi200056r9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"1","key":"noi200056r10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"2","key":"noi200056r11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"16","key":"noi200056r12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"noi200056r13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"9967","key":"noi200056r14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"noi200056r15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a case with fatal CAR T-cell-associated cerebral edema.","volume":"77","author":"Torre","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"noi200056r16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell\u2013mediated neurotoxicity in nonhuman primates.","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"issue":"25","key":"noi200056r17","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"noi200056r18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"355","key":"noi200056r19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"noi200056r20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort.","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"issue":"6","key":"noi200056r21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"noi200056r22","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"issue":"22","key":"noi200056r24","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma.","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"noi200056r25","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"18","key":"noi200056r26","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"noi200056r27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"4","key":"noi200056r29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"noi200056r23","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03. Updated June 14, 2010. Accessed July 1, 2020. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"noi200056r28","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 5.0. Published November 27, 2017. Accessed July 1, 2020. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2769021\/jamaneurology_rubin_2020_oi_200056_1607448136.91961.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T13:40:48Z","timestamp":1607953248000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2769021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.2703","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}